此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Autus 阀门早期可行性研究

2026年10月15日 更新者:Edwards Lifesciences

用于外科肺动脉瓣置换早期可行性研究的 Autus 尺寸可调瓣膜

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

研究概览

地位

主动,不招人

研究类型

介入性

注册 (实际的)

62

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Los Angeles、California、美国、90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago、Illinois、美国、60611
        • Ann and Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan - Mott Children's Hospital
    • New York
      • New York、New York、美国、10032
        • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
    • North Carolina
      • Durham、North Carolina、美国、27703
        • Duke University
    • Ohio
      • Columbus、Ohio、美国、43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City、Utah、美国、84113
        • University of Utah - Intermountain Primary Children's Hospital
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 16年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

    1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
    2. Moderate or greater pulmonary regurgitation;
    3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
  6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).

  7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.

  8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.
  2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
  4. Subject has pulmonary atresia and major aortopulmonary collaterals.
  5. Subject has significant peripheral pulmonary artery stenosis.
  6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
  7. Subject has active endocarditis or a history of infective endocarditis.
  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
  13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
  14. Subject needs emergency cardiac or vascular surgery or intervention.
  15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
  17. Subject or parent/legal representative refuses blood transfusions.
  18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
  19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Autus Valve Arm

Pulmonary Valve Replacement Surgery with the Autus Valve

Pulmonary valve replacement surgery with the Autus Valve

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Valve Implantation Primary Safety Endpoint
大体时间:30 Days post-valve implantation

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
30 Days post-valve implantation
Valve Implantation Primary Effectiveness Endpoint
大体时间:6 Months post-valve implantation

Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:

  • A mean RVOT gradient less than or equal to 40 mmHg and
  • Less than moderate pulmonary regurgitation by transthoracic echo and
  • No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.
6 Months post-valve implantation

其他结果措施

结果测量
措施说明
大体时间
Other Safety Outcome - Composite
大体时间:6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Mortality
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Mortality, including: all cause, cardiac-related, procedure-related and device-related

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve Thrombosis
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Valve thrombosis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Thromboembolism
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Thromboembolism

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Cardiac or Valve Intervention
大体时间:30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Other cardiac or valve intervention (surgical or transcatheter)

30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
Other Safety Outcome - Major Hemorrhage
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Major hemorrhage

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Endocarditis
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Endocarditis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Hemolysis
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Hemolysis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Device Explantation
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Device explantation

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Adverse Events (AE)
大体时间:30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Adverse events

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve/Stent Fracture
大体时间:pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.

An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.

pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
大体时间:Immediately Post-Valve Implant Procedure

To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):

  • RV to PA peak systolic pressure gradient <40 mmHg (direct pressure measurement);
  • None or trivial pulmonary regurgitation (assessed via TEE);
  • No paravalvular leak (assessed via TEE).
Immediately Post-Valve Implant Procedure
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
大体时间:Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Pulmonary Stenosis Grade
大体时间:Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Right Ventricular Measures
大体时间:Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Left Ventricular Measures
大体时间:Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Modified Ross Functional Classification
大体时间:Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Modified Ross Functional Class as assessed by the Site Investigators

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - PedsQL - Cardiac Module
大体时间:Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.

The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.

Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
Other Post-Implant Valve Expansion Safety Outcome - Composite
大体时间:30 days after each post-implant valve expansion procedure

Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:

  • Death;
  • Extracorporeal membrane oxygenation (ECMO) support;
  • Unplanned intervention (surgical or transcatheter);
  • Major hemorrhage
30 days after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
大体时间:Immediately after each post-implant valve expansion procedure

To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:

  • RV to aortic systolic pressure ratio: ≤0.5.
  • Peak-to-peak RV to PA systolic pressure gradient: ≤15 mmHg;
  • Peak-to-peak RV to PA systolic pressure gradient: ≥50% reduction (pre vs post valve expansion).
Immediately after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
大体时间:6 months after each post-implant valve expansion procedure

Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:

  • Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;
  • Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.
6 months after each post-implant valve expansion procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年2月5日

初级完成 (实际的)

2026年8月24日

研究完成 (估计的)

2036年2月5日

研究注册日期

首次提交

2021年7月23日

首先提交符合 QC 标准的

2021年8月12日

首次发布 (实际的)

2021年8月16日

研究记录更新

最后更新发布 (实际的)

2026年10月20日

上次提交的符合 QC 标准的更新

2026年10月15日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅